Cargando…

A Review of Contact Lens Dropout

PURPOSE: Contact lens (CL) dropout is likely a major factor contributing to the near stagnant growth in the CL market. The purpose of this review is to summarize the current state of knowledge related to the frequency of CL dropout and the factors associated with it. METHODS: PubMed.gov was searched...

Descripción completa

Detalles Bibliográficos
Autores principales: Pucker, Andrew D, Tichenor, Anna A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323801/
https://www.ncbi.nlm.nih.gov/pubmed/32612404
http://dx.doi.org/10.2147/OPTO.S198637
Descripción
Sumario:PURPOSE: Contact lens (CL) dropout is likely a major factor contributing to the near stagnant growth in the CL market. The purpose of this review is to summarize the current state of knowledge related to the frequency of CL dropout and the factors associated with it. METHODS: PubMed.gov was searched on or before March 22, 2020, with the terms “contact lens” with “dropout” or “cessation” or “disruption” or “discomfort”. Pertinent articles were collected. The references from these articles were likewise searched to identify additional relevant articles. Only manuscripts written in English were included. No study design or date exclusions were imposed on this review. RESULTS: This literature review found that CL dropout was frequent across developed countries, with a CL dropout frequency that ranged between 12.0% and 27.4% (pooled mean = 21.7%). The top cited reason for CL dropout in established CL wearers was discomfort, while vision was the top reason in neophyte CL wearers. If given the chance, CL dropouts are often able to successfully resume CL wear up to 74% of the time. While the literature is mixed with regard to factors promoting CL dropout, meibomian gland dysfunction appears to promote CL dropout. CONCLUSION: CL dropout is a frequently encountered condition that may be curtailed by early detection, patient education, alterative CL options, or early treatment of underlying ocular surface diseases such as meibomian gland dysfunction.